IP Library Granted Patent US 12,521,559
Granted Patent B2
US 12,521,559 · App. 17/770,707 · Granted Jan 13, 2026

Methods for planning and delivering cardiac electrical stimulation

Inventors: David Prutchi (Voorhees, NJ); Simeon Ioannis Kedikoglou (Tallahassee, FL); Angela Connolly Stagg (Allendale, NJ); Tamir Ben David (Tel-Aviv, IL)
Assignee: Impulse Dynamics NV
A61N1/36585A61N1/3624A61N1/3628A61N1/36592
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,521,559
App. No.
17/770,707
Granted
Jan 13, 2026
Kind
B2
Abstract

A system for cardiac electrical stimulation treatment, comprising: an implantable pulse generator; one or more leads extending from the pulse generator to the heart for applying cardiac electrical stimulation; a controller programmed with at least one treatment plan for applying cardiac electrical stimulations, the controller configured to automatically update the treatment plan in response to actual cardiac activity by updating one or more parameters including: a time period during which cardiac electrical stimulations are applied; a rate of cardiac electrical stimulations; an amount of energy delivered at each cardiac electrical stimulation.

Claims (56)

1 . A method of operating a cardiac electrical stimulation device, the device comprising a memory in which an initial treatment plan is defined, the initial treatment plan including parameters according to which cardiac electrical stimulations are applied to the heart; the method comprising:

generating, via a device controller and according to said initial treatment plan, commands for electrifying one or more leads of said device with a cardiac electrical stimulation signal;

sensing actual cardiac activity using one or more sensors;

changing the commands to adapt the treatment to said actual cardiac activity as sensed by said one or more sensors;

automatically generating an updated treatment plan, at said device controller, at least one of said parameters to compensate for changes made relative to said initial treatment plan due to said sensed actual cardiac activity;

selecting, in the updated treatment plan, a parameter representing a total number of stimulations to be delivered to the heart over a first selected period of time;

generating commands to deliver stimulations to the heart, wherein said generating takes into account said selecting; and

counting the number of stimulations generated;

when the number of stimulations generated during the first selected time period is lower than said selected total number of stimulations, adding a second selected time period at an extent sufficient to deliver the required additional stimulations.

2 . The method according to claim 1 , wherein said parameters include one or more of: a rate of cardiac electrical stimulations; a time period over which cardiac electrical stimulations are to be applied; stimulation current; an output voltage; a duration of each stimulation.

3 . The method according to claim 2 , wherein said automatically generating an updated treatment plan comprises one or more of: increasing or reducing said rate of cardiac electrical stimulations; lengthening or shortening said time period over which cardiac electrical stimulations are applied; increasing or reducing said stimulation current intensity; lengthening or shortening said stimulation duration.

4 . The method according to claim 1 , wherein said parameters are selected and/or updated to obtain a total number of cardiac electrical stimulations and/or a total amount of cardiac electrical stimulation energy.

5 . The method according to claim 1 , wherein said initial treatment plan is defined and/or updated according to measured and/or received input of cardiac activity characteristics of a patient being treated.

6 . The method according to claim 5 , wherein said cardiac activity characteristics include: average heart rate, average stroke volume, occurrence rate of irregular cardiac events.

7 . The method according to claim 5 , wherein said actual cardiac activity comprises irregular cardiac events from the group of: premature ventricular contraction (PVC), atrial arrhythmia or ventricle arrhythmia.

8 . The method according to claim 1 , wherein said device is an implanted device and wherein said one or more leads contact the ventricular septum of the heart.

9 . The method according to claim 1 , comprising measuring said actual cardiac activity using said one or more sensors.

10 . The method according to claim 1 , wherein said initial treatment plan is defined according to at least one of:

one or more thresholds of a heart rate during which said commands are to be generated; and

one or more physical states of the patient during which said commands are to be generated.

11 . The method according to claim 1 , wherein said automatically generating an updated treatment plan is performed in response to one or more skipped cardiac electrical stimulations.

12 . The method according to claim 1 , wherein said automatically generating an updated treatment plan is performed if at least one of the following:

a number of cardiac electrical stimulations that were actually delivered is lower than a planned number of cardiac electrical stimulations; and

a total amount of cardiac electrical stimulation energy delivered is lower than a planned amount of cardiac electrical stimulation energy.

13 . The method according to claim 1 , wherein said cardiac electrical stimulation comprises cardiac contractility modulation stimulation.

14 . The method according to claim 1 , comprising adding said second selected time period to generate additional stimulations when said number of stimulations generated is lower than 90% of said selected total number of stimulations.

15 . The method according to claim 1 , wherein said adding a second selected time period comprises extending said first selected period of time.

16 . The method according to claim 1 , comprising, when said number of stimulations generated during the first selected time period is lower than said selected total number of cardiac electrical stimulations, reducing said selected total number of cardiac electrical stimulations for a future stimulation session.

17 . The method according to claim 1 , wherein said first selected time period is between 4 hours-8 hours a day.

18 . The method of claim 1 , further comprising:

selecting the parameter of a total amount of energy to be delivered by cardiac electrical stimulations to the heart, of said updated treatment plan; and

selecting one or both of: a time period during which cardiac electrical stimulations are to be applied to the heart, and stimulation current intensity for each of the stimulations of a first treatment session, said time period and said stimulation current intensity selected so as to reach said selected total amount of energy.

19 . The method according to claim 18 , further including determining one or both of an adjustment of said time period and an adjustment of said stimulation current intensity for a second treatment session, said determining based on measured cardiac activity during said first treatment session.

20 . A system for cardiac electrical stimulation treatment, comprising:

an implantable pulse generator;

one or more leads extending from said pulse generator to the heart for applying cardiac electrical stimulation;

a controller programmed with at least one treatment plan for applying cardiac electrical stimulations, said controller configured to automatically generate an updated treatment plan in response to measured cardiac activity by updating one or more parameters including: a time period during which cardiac electrical stimulations are applied; a total number of cardiac electrical stimulations; a total amount of cardiac electrical stimulation energy; and an amount of energy delivered at each cardiac electrical stimulation;

wherein said controller is configured to automatically generate said updated treatment plan when a number of cardiac electrical stimulations that were actually delivered is lower than a planned number of cardiac electrical stimulations.

21 . The system according to claim 20 , comprising one or more sensors including an ECG sensor configured for measuring said actual cardiac activity.

22 . The system according to claim 21 , wherein said controller is configured to deduce one or more of: an average heart rate, an average stroke volume, an occurrence rate of irregular cardiac events based on data acquired by said one or more sensors.

23 . The system according to claim 22 , wherein said irregular cardiac events are from the group of: premature ventricular contraction (PVC), atrial arrhythmia or ventricle arrhythmia.

24 . The system according to claim 20 , wherein said one or more leads are adapted to contact the ventricular septum of the heart.

25 . The system according to claim 20 , wherein said controller is programmed with instructions for automatically generating said updated treatment plan, said instructions suitable to compensate for real time changes in said treatment plan.

26 . The system according to claim 25 , wherein said instructions include numerical factors according to which one or more of the following parameters are updated: stimulation current intensity; output voltage which sets a selected stimulation current intensity; stimulation duration; treatment session duration; stimulation rate.

27 . The system according to claim 20 , wherein said controller is configured to select and/or update parameters to obtain a total number of cardiac electrical stimulations and/or a total amount of cardiac stimulation energy.

28 . The system according to claim 20 , wherein said controller is configured for: increasing or reducing a rate of cardiac electrical stimulations; lengthening or shortening said time period over which cardiac electrical stimulations are applied; increasing or reducing stimulation current intensity; lengthening or shortening a stimulation duration.

29 . The system according to claim 20 , wherein said controller is configured to at least one of:

set and/or receive as input one or more thresholds of a heart rate during which said cardiac electrical stimulations are applied; and

set and/or receive as input one or more physical states of the patient during which said cardiac electrical stimulations are applied.

30 . The system according to claim 20 , wherein said controller is configured to automatically generate said updated treatment plan in response to one or more skipped cardiac electrical stimulations.

31 . The system according to claim 20 , wherein said controller is configured to set a number of cardiac electrical stimulations to be delivered within a set time period.

32 . A system for cardiac electrical stimulation treatment, comprising:

an implantable pulse generator;

one or more leads extending from said pulse generator to the heart for applying cardiac electrical stimulation;

a controller programmed with at least one treatment plan for applying cardiac electrical stimulations, said controller configured to automatically generate an updated treatment plan in response to measured cardiac activity by updating one or more parameters including: a time period during which cardiac electrical stimulations are applied; a total number of cardiac electrical stimulations; a total amount of cardiac electrical stimulation energy; and an amount of energy delivered at each cardiac electrical stimulation;

wherein said controller is configured to set a number of cardiac electrical stimulations to be delivered within a set time period of 24 hours.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 7, 2024
From: KENNEDY LEWIS INVESTMENT MANAGEMENT LLC
To: IMPULSE DYNAMICS N.V.
Reel/Frame 069118/0961 →
SECURITY INTEREST Recorded May 23, 2024
From: IMPULSE DYNAMICS, N.V.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 067526/0072 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 19, 2022
From: IMPULSE DYNAMICS N.V.
To: KENNEDY LEWIS INVESTMENT MANAGEMENT LLC, AS COLLATERAL AGENT
Reel/Frame 060120/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2022
From: PRUTCHI, DAVID; KEDIKOGLOU, SIMEON IOANNIS; CONNOLLY STAGG, ANGELA; BEN DAVID, TAMIR
To: IMPULSE DYNAMICS NV
Reel/Frame 059855/0934 →
Continuity (5)
Provisional Application 62924782 · Oct 23, 2019
Provisional Application 62924776 · Oct 23, 2019
Provisional Application 63042061 · Jun 22, 2020
Provisional Application 63001343 · Mar 29, 2020
Related Publication 20220379120A1 · Dec 1, 2022
References Cited (147)
US 4554922A · Prystowsky et al. · 1985 [cited by applicant]
US 5372607A · Stone et al. · 1994 [cited by applicant]
US 6233487B1 · Mika et al. · 2001 [cited by applicant]
US 6263242B1 · Mika et al. · 2001 [cited by applicant]
US 6269268B1 · Callaghan · 2001 [cited by examiner]
US 6370430B1 · Mika et al. · 2002 [cited by applicant]
US 6480737B1 · Policker et al. · 2002 [cited by applicant]
US 6597952B1 · Mika et al. · 2003 [cited by applicant]
US 6725093B1 · Ben-Haim et al. · 2004 [cited by applicant]
US 6993385B1 · Routh et al. · 2006 [cited by applicant]
US 7027863B1 · Prutchi et al. · 2006 [cited by applicant]
US 7519426B1 · Koh et al. · 2009 [cited by applicant]
US 7634310B2 · Lee et al. · 2009 [cited by applicant]
US 7953481B1 · Shemer et al. · 2011 [cited by applicant]
US 7991469B2 · Schwartz et al. · 2011 [cited by applicant]
US 8634910B2 · Stahmann · 2014 [cited by applicant]
US 8977353B2 · Rousso et al. · 2015 [cited by applicant]
US 9713723B2 · Shemer et al. · 2017 [cited by applicant]
US 10207110B1 · Gclfand et al. · 2019 [cited by applicant]
US 20030036777A1 · Sheth et al. · 2003 [cited by applicant]
US 20040127804A1 · Hatlesad et al. · 2004 [cited by applicant]
US 20050039745A1 · Stahmann et al. · 2005 [cited by applicant]
US 20050085867A1 · Tehrani et al. · 2005 [cited by applicant]
US 20050090871A1 · Cho et al. · 2005 [cited by applicant]
US 20060100668A1 · Ben-David et al. · 2006 [cited by applicant]
US 20060224190A1 · Gill et al. · 2006 [cited by applicant]
US 20070060962A1 · Pappone · 2007 [cited by applicant]
US 20070162079A1 · Shemer · 2007 [cited by examiner]
US 20080021336A1 · Dobak, III · 2008 [cited by applicant]
US 20080103532A1 · Armstrong et al. · 2008 [cited by applicant]
US 20080114411A1 · Lian et al. · 2008 [cited by applicant]
US 20080275520A1 · Hoppcr et al. · 2008 [cited by applicant]
US 20090030471A1 · Rousso et al. · 2009 [cited by applicant]
US 20090062882A1 · Zhang et al. · 2009 [cited by applicant]
US 20090248101A1 · Anker · 2009 [cited by applicant]
US 20090287103A1 · Pillai · 2009 [cited by applicant]
US 20100069977A1 · Stahmann · 2010 [cited by applicant]
US 20100069985A1 · Stahmann · 2010 [cited by applicant]
US 20100087892A1 · Stubbs et al. · 2010 [cited by applicant]
US 20100248288A1 · Iiess et al. · 2010 [cited by applicant]
US 20100305647A1 · McCabe et al. · 2010 [cited by applicant]
US 20110152956A1 · Hincapie-Ordonez et al. · 2011 [cited by applicant]
US 20130006319A1 · Doerr · 2013 [cited by applicant]
US 20130138006A1 · Bornzin et al. · 2013 [cited by applicant]
US 20130218222A1 · Doerr · 2013 [cited by applicant]
US 20130245722A1 · Ternes et al. · 2013 [cited by applicant]
US 20140046392A1 · Stubbs · 2014 [cited by examiner]
US 20160045732A1 · Grenz et al. · 2016 [cited by applicant]
US 20170245794A1 · Sharma · 2017 [cited by examiner]
US 20170348524A1 · Matos · 2017 [cited by applicant]
US 20180214698A1 · Cuchiara · 2018 [cited by applicant]
US 20190060632A1 · Asirvatham et al. · 2019 [cited by applicant]
US 20190329043A1 · Sharma · 2019 [cited by examiner]
US 20190329052A1 · Kim et al. · 2019 [cited by applicant]
US 20220387790A1 · Prutchi et al. · 2022 [cited by applicant]
US 20220387795A1 · Prutchi et al. · 2022 [cited by applicant]
US 20230001204A1 · Prutchi et al. · 2023 [cited by applicant]
US 20230173280A1 · Prutchi et al. · 2023 [cited by applicant]
CA 2459408 · 2003 [cited by applicant]
CN 1787850 · 2006 [cited by applicant]
CN 1882296 · 2006 [cited by applicant]
CN 101827629 · 2010 [cited by applicant]
CN 104321107 · 2015 [cited by applicant]
CN 105813687 · 2016 [cited by applicant]
CN 107261324 · 2017 [cited by applicant]
EP 0334675 · 1989 [cited by applicant]
EP 0600631 · 1994 [cited by applicant]
EP 0910429 · 1999 [cited by applicant]
EP 2659931 · 2013 [cited by applicant]
JP 2007503286 · 2007 [cited by applicant]
JP 2008532630 · 2008 [cited by applicant]
JP 2010104750 · 2010 [cited by applicant]
JP 2011502552 · 2011 [cited by applicant]
JP 2012502729 · 2012 [cited by applicant]
JP 2012504468 · 2012 [cited by applicant]
JP 2015503397 · 2015 [cited by applicant]
WO WO2004080533 · 2004 [cited by applicant]
WO WO2010039877 · 2010 [cited by applicant]
WO WO2021079316 · 2021 [cited by applicant]
WO WO2021079318 · 2021 [cited by applicant]
WO WO2021079319 · 2021 [cited by applicant]
WO WO2021198755 · 2021 [cited by applicant]
Interview Summary Dated Nov. 12, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/857,085. (8 pages). [cited by applicant]
International Search Report and the Written Opinion Dated Feb. 4, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/059949. (14 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Aug. 12, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/059947. (16 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Jan. 14, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/059943. (17 Pages). [cited by applicant]
International Search Report and the Written Opinion Dated Aug. 20, 2021 From the International Searching Authority Re. Application No. PCT/IB2020/059944. (18 Pages). [cited by applicant]
Invitation to Pay Additional Fees, Communication Relating to the Result of the Partial International Search and the Provisional Opinion Dated Apr. 20, 2021 From the International Searching Authority Re. Application No. … [cited by applicant]
Invitation to Pay Additional Fees, Communication Relating to the Result of the Partial International Search and the Provisional Opinion Dated Apr. 26, 2021 From the International Searching Authority Re. Application No. … [cited by applicant]
Written Opinion Dated Mar. 15, 2022 From the International Searching Authority Re. Application No. PCT/IB2020/059944. (9 Pages). [cited by applicant]
Abi-Samra et al. “Cardiac Contractility Modulation: A Novel Approach for the Treatment of Heart Failure”, Heart Fail Reviews 21:645-660, Jul. 9, 2016. [cited by applicant]
Abraham et al. “A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation in Patients With Moderately Reduced Left Ventricular Ejection Fraction and a Narrow QRS Duration: Stu… [cited by applicant]
Abraham et al. “A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation”, Journal of the American College of Cardiology, JACC: Heart Failure, 6(10): 874-883, Published Onlin… [cited by applicant]
Abraham et al. “Subgroup Analysis of a Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure”, Journal of Cardiac Failure, 17(9): 710-717, Published… [cited by applicant]
Anker et al. “Cardiac Contractility Modulation Improves Long-Term Survival and Hospitalizations in Heart Failure With Reduced Ejection Fraction”, European Journal of Heart Failure, 21(9): 1103-1113, Published Online Jan… [cited by applicant]
Borggrcfc ct al. “Randomizcd, Doublc Blind Study of Non-Excitatory, Cardiac Contractility Modulation Elcctrical Impulscs for Symptomatic Hcart Failurc”, European Heart Journal, 29(8): 1019-1028, Published Online Feb. 12… [cited by applicant]
Giallauria et al. “Effects of Cardiac Contractility Modulation by Non-Excitatory Electrical Simulation on Exercise Capacity and Quality of Life: An Individual Patient's Data Meta-Analysis of Randomized Controlled Trials… [cited by applicant]
Ibrahim et al. “Power Prior Distributions for Regression Models”, Statistical Science, 15(1): 46-60, Feb. 2000. [cited by applicant]
Kadish et al. “A Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure”, American Heart Journal, 161(2): 329-337, Feb. 2011. [cited by applicant]
Kuschyk et al. “Efficacy and Survival in Patients With Cardiac Contractility Modulation: Long-Term Single Center Experience in 81 Patients”, International Journal of Cardiology, 183: 76-81, Available Online Jan. 20, 201… [cited by applicant]
Liu et al. “Improvement of Long-Term Survival by Cardiac Contractility Modulation in Heart Failure Patients: A Case-Control Study”, International Journal of Cardiology, 206: 122-126, Available On line Jan. 6, 2016. [cited by applicant]
Lyon et al. “Cardiac Contractility Modulation Therapy in Advanced Systolic Heart Failure”, Nature Reviews Cardiology, XP0557621686, 10(10): 584-598, Advance Online Publication Aug. 13, 2013. [cited by applicant]
Mando et al. “Outcomes of Cardiac Contractility Modulation: A Systemic Review and Meta-Analysis of Randomized Clinical Trials”, Cardiovascular Therapeutics, 2019(Art.ID 9769724): 1-10, Jun. 17, 2019. [cited by applicant]
Mueller et al. “Clinical Effects of Long-Term Cardiac Contractility Modulation (CCM) in Subjects With Heart Failure Caused by Left Ventricular Systolic Dysfunction”, Clinical Research of Cardiology, 106(11): 893-904, Pu… [cited by applicant]
Neelagaru et al. “Nonexcitatory, Cardiac Contractility Modulation Electrical Impulses: Feasibility Study for Advanced Heart Failure in Patients With Normal QRS Duration”, Heart Rythm, 3(10): 1140-1147, Published Online … [cited by applicant]
Schocnc ct al. “Cardiac Contractility Modulation Providcs Improvcd Vcntilatory Efficicncy and Rcduccs Oscillatory Brcathing Pattcrn”, Europcan Hcart Journal, Poster Session 4: Advanced Heart Failure, 40(Suppl.1): 2133: … [cited by applicant]
Schuirmann “Pharmacometrics: A Comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability”, Journal of Pharmacokinetics and Biopharmaceutics, 15(6): 6… [cited by applicant]
Tint et al. “New Generation Cardiac Contractility Modulation Device—Filling the Gap in Heart Failure Treatment”, Journal of Clinical Medicine, 8(5): 588-1-588-10, Apr. 29, 2019. [cited by applicant]
Tschoepe et al. “Cardiac Contractility Modulation: Mechanisms of Action in Heart Failure with Reduced Ejection Fraction and Beyond”, European Journal of Heart Failure, 21(1):14-20, Nov. 28, 2018. [cited by applicant]
Uskach et al. “Possibilities and Perspectives of Using Cardiac Contractility Modulation in Patients With Chronic Heart Failure and Atrial Fibrillation”, Kardiologiia, 59(2S): 4-14, 2019 & English Abstract. [cited by applicant]
Wang et al. “Meta-Analysis of the Incidence of Lead Dislodgement With Conventional and Leadless Pacemaker Systems”, Pacing and Clinical Electrophysiology, Pace, 41(10): 1365-1371, Published Online Aug. 27, 2018. [cited by applicant]
Yu et al. “Impact of Cardiac Contractility Modulation on Left Ventricular Global and Regional Function and Remodeling”, Journal of the American College of Cardiology, JACC: Cardiovascular Imaging, 2(12): 1341-1349, Dec.… [cited by applicant]
Notice of Reason(s) for Rejection Dated Jun. 11, 2024 From the Japan Patent Office Re. Application No. 2022-523998 and Its Translation Into English. (10 Pages). [cited by applicant]
Notice of Reason(s) for Rejection Dated Jun. 6, 2024 From the Japan Patent Office Re. Application No. 2022-523513 and Its Translation Into English. (12 Pages). [cited by applicant]
Notice of Reason(s) for Rejection Dated 28-May 2024 From the Japan Patent Office Re. Application No. 2022-523514 and Its Translation Into English. (14 Pages). [cited by applicant]
Notice of Reason(s) for Rejection Dated Mar. 4, 2025 From the Japan Patent Office Re. Application No. 2022-523514 and Its Translation Into English. (12 Pagcs). [cited by applicant]
Notice of Reason(s) for Rejection Dated Feb. 12, 2025 From the Japan Patent Office Re. Application No. 2022-523998 and Its Translation Into English. (9 Pages). [cited by applicant]
Official Action Dated Feb. 6, 2025 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/911,676. (48 pages). [cited by applicant]
Restriction Official Action Dated Dec. 30, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/770,318. (5 pages). [cited by applicant]
Oliver et al. “Anatomy, Thorax, Phrenic Nerves”, Europe PMC, Search life-sciences literature, Study Guide from StatPearls Publishing, Treasure Island (FL), PMID: 30020697, Jul. 19, 2018. dowloaded from https://europepmc… [cited by applicant]
El Shear “Novel Paradigms in the Therapeutic Management of Heart Failure With Preserved Ejection Fraction: Clinical Perspectives”, American Journal of Cardiovascular Disease, 9(5): 91-108, Oct. 15, 2019. [cited by applicant]
Tschöpe et al. “Cardiac Contractility Modulation Signals Improve Exercise Intolerance and Maladaptive Regulation of Cardiac Key Proteins for Systolic and Diastolic Function in HFpEF”, International Journal of Cardiology… [cited by applicant]
Zile et al. “New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I. Diagnosis, Prognosis, and Mcasurcmcnts of Diastolic Function”, Circulation, 105(11): 1387-1393, Mar. 19, 2002. [cited by applicant]
Zile et al. “New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part II. Causal Mechanisms and Treatment”, Circulation, 105(12): 1503-1508, Mar. 26, 2002. [cited by applicant]
Official Action Dated Mar. 20, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/770,329. (39 pages). [cited by applicant]
Additional Search Fees Due under Rule 164(2)(a) EPC Dated Feb. 26, 2025 From the European Patent Office Re. Application No. 20803263.1 (5 pages). [cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Dec. 22, 2023 From the European Patent Office Re. Application No. 20801017.3 (4 Pages). [cited by applicant]
International Preliminary Report on Patentability Dated May 5, 2022 From the International Bureau of WIPO Re. Application No. PCT/IB2020/059943. (8 Pages). [cited by applicant]
International Preliminary Report on Patentability Dated May 5, 2022 From the International Bureau of WIPO Re. Application No. PCT/IB2020/059947. (10 Pages). [cited by applicant]
International Preliminary Report on Patentability Dated May 5, 2022 From the International Bureau of WIPO Re. Application No. PCT/IB2020/059949. (10 Pages). [cited by applicant]
Official Action Dated Jan. 17, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/857,085. (11 pages). [cited by applicant]
Official Action Dated Aug. 5, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/857,085. (21 pages). [cited by applicant]
Cleveland Clinic “Hypertrophic Cardiomyopathy”, Cleveland Clinic, Retrieved Online, pp. 1-2, 2021. [cited by applicant]
Meluzin et al. “Noninvasive Prediction of the Exercise-Induced Elevation in Left Ventricular Filling Pressure in Post-Heart Transplant Patients With Normal Left Ventricular Ejection Fraction”, Clinical Cardiology, 18(2)… [cited by applicant]
Official Action Dated Oct. 11, 2024 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/770,329. (26 pages). [cited by applicant]
Notice of Reasons for Rejection Dated Dec. 3, 2024 From the Japan Patent Office Re. Application No. 2022-523513 and Its Translation into English. (12 Pages). [cited by applicant]
Official Action Dated Sep. 8, 2023 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/857,085. (24 pages). [cited by applicant]
Eisman et al. “Pulmonary Capillary Wedge Pressure Patterns During Exercice Predict Exercise Capacity and Incident Heart Failure”, Circulation: Heart Failure, 11(5): 1-9, May 2018. [cited by applicant]
Meluzin et al. “Improvement in the Prediction of Exercise-Induced Elevation of Left Ventricular Filling Pressure in Patients With Normal Left Ventricular Ejection Fraction”, Echocardiography, 34(1): 78-86, Oct. 25, 2016… [cited by applicant]
International Preliminary Report on Patentability Dated Jul. 21, 2022 From the International Preliminary Examining Authority Re. Application No. PCT/IB2020/059944. (21 Pages). [cited by applicant]
Interview Summary Dated Mar. 21, 2025 from the US Patent and Trademark Office Re. U.S. Appl. No. 17/770,329. (8 pages). [cited by applicant]
Notification of Office Action and Search Report Dated Apr. 1, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080089348.6 and Its Machine Translation of Office A… [cited by applicant]
Notification of Office Action and Search Report Dated Mar. 19, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080088570.4 and its Translation of the Office Acti… [cited by applicant]
Notification of Office Action and Search report Dated Mar. 21, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080090192.3 and Its Translation in English (18 Pag… [cited by applicant]
Notification of Office Action and Search Report Dated Mar. 26, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080101268.8 and Its Machine Translation of Office … [cited by applicant]
Communication Pursuant to Article 94(3) EPC Dated Nov. 11, 2025 From the European Patent Office Re. Application No. 20803265.6 (4 Pages). [cited by applicant]
Notification of Office Action and Search Report Dated Nov. 6, 2025 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 202080088570.4 and its Machine Translation of the Offi… [cited by applicant]